Bill Grossman

Bill is the former Senior Vice President and Therapeutic Area Head of Oncology Clinical Development at Gilead Sciences Inc. overseeing the company’s Oncology portfolio and collaboration programs. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences and Bellicum Pharmaceuticals. He has held additional leadership roles at Merck, Biothera, AbbVie and Genentech/Roche.

Bill has more than 25 years of experience in oncology, having begun his career as a practicing hematologist/oncologist with expertise in bone marrow transplants before moving into the biopharmaceutical industry. At the Medical College of Wisconsin, he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. In addition, Bill serves on the Board of Directors for Day One Biopharmaceuticals (recently acquired by Servier), enGene Therapeutics, and the Advisory Boards of Ginkgo Bioworks, Noetik, Bolt Biotherapeutics, and LTZ Therapeutics.

Bill received his MD and PhD in Immunology from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical and post-doctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.